What is the Share Price of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd share price is ₹81.58 As on 19 December, 2024|00:43

Home
>
Stocks
>
Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd Share Price

Q: What is the Market Cap of Bafna Pharmaceuticals Ltd?

The Market Cap of Bafna Pharmaceuticals Ltd is ₹189 As on 19 December, 2024|00:43

Q: What is PE Ratio of Bafna Pharmaceuticals Ltd?

The P/E ratio of Bafna Pharmaceuticals Ltd is 246 As on 19 December, 2024|00:43

Q: What is PB Ratio of Bafna Pharmaceuticals Ltd?

The PB ratio of Bafna Pharmaceuticals Ltd is 0.38 As on 19 December, 2024|00:43

₹ 81.58 +0.59 (0.73%)
Updated on 18-12-2024 4:38 PM

Stock Rating

Pros 1

Cons 6

Bafna Pharmaceuticals Ltd Price Performance

Day's Low
₹80

Day's High
₹81.65

₹ 81.58

52-w low
₹73.25

52-w high
₹113

81.58

Day's open
₹80
Previous close
₹80.989998
VWAP
₹81.46
Lower price band
₹76.94
Upper price band
₹85.03

Today's Market Action

The last traded share price of Bafna Pharmaceuticals Ltd was 81.58 up by 0.73% on the NSE. Its last traded stock price on BSE was 78.00 down by -2.19%. The total volume of shares on NSE and BSE combined was 972 shares. Its total combined turnover was Rs 0.01 crores.

Bafna Pharmaceuticals Ltd Medium and Long Term Market Action

Bafna Pharmaceuticals Ltd hit a 52-week high of 113 on 07-05-2024 and a 52-week low of 73.25 on 24-06-2024. The stock price of Bafna Pharmaceuticals Ltd is up by 2% over the last one month. It is down by -20.41% over the last one year. Don't forget to check the full stock price history in the table below.

Bafna Pharmaceuticals Ltd Fundamentals

Market Cap (Cr): 189
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Bafna Pharmaceuticals Ltd Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Bafna Pharmaceuticals Ltd Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About Bafna Pharmaceuticals Ltd

Data not available.

Bafna Pharmaceuticals Ltd FAQ's

What is Share Price of Bafna Pharmaceuticals Ltd?

What is the Market Cap of Bafna Pharmaceuticals Ltd?

What is PE Ratio of Bafna Pharmaceuticals Ltd?

What is PB Ratio of Bafna Pharmaceuticals Ltd?

What is the CAGR of Bafna Pharmaceuticals Ltd?

How to Buy Bafna Pharmaceuticals Ltd Share?

Financials

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

Zero Debt
The company has almost nil to negligible debt to equity ratio of 0.06. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.

Cons

Low Sustainable RoE
The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
Low Return on Capital Employed
The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
Low Pricing Power & High Competition
The business has extremely low pricing power and is vulnerable to competitive pressure which can significantly impact shareholder returns.
Capital Intensive Business
The company operates an extremely capital intensive business with a low Asset turnover ratio of 1.20. A low asset turnover ratio negatively impacts RoE and reduces shareholder returns. Also due to the capital intensive nature of business, growth of the business would need to be funded either via increasing borrowings or diluting shareholders, both of which shall negatively impact shareholder value and returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 152 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
Poor Corporate Governance
The general corporate governance standards of the company are poor which can negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(19/12/2024)

Margin of Safety Index: High

0% People are bullish about Bafna Pharmaceuticals Ltd

0 % People are bearish about Bafna Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %